FAM83B mediates EGFR- and RAS-driven oncogenic transformation.
暂无分享,去创建一个
Sarah A. Scott | Rocky Cipriano | G. Stark | H. Brown | M. Jackson | Rocky Cipriano | K. Miskimen | H Alex Brown | George R Stark | B. Bryson | Kristy L S Miskimen | Benjamin L Bryson | Mark W Jackson | Sarah A Scott | James Graham | Ronald C Bruntz | J. Graham | Ronald C. Bruntz | James Graham | Ronald C. Bruntz | Sarah A. Scott | H. Alex Brown | George R. Stark
[1] L. Mayo,et al. Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis , 2010, Cell cycle.
[2] H. Brown,et al. Biochemical analysis of phospholipase D. , 2007, Methods in enzymology.
[3] M. Jackson,et al. TGF-β signaling engages an ATM-CHK2-p53–independent RAS-induced senescence and prevents malignant transformation in human mammary epithelial cells , 2011, Proceedings of the National Academy of Sciences.
[4] M. Jackson,et al. MdmX Protects p53 from Mdm2-Mediated Degradation , 2000, Molecular and Cellular Biology.
[5] J. Exton,et al. Association of N- and C-terminal Domains of Phospholipase D Is Required for Catalytic Activity* , 1998, The Journal of Biological Chemistry.
[6] P. Pandolfi,et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.
[7] Weifeng Chen,et al. BJ-TSA-9, a novel human tumor-specific gene, has potential as a biomarker of lung cancer. , 2005, Neoplasia.
[8] G. Stark,et al. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53 , 2004, Oncogene.
[9] C. Ottmann,et al. Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling , 2010, Molecular and Cellular Biology.
[10] Richard Marais,et al. The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.
[11] David L. Brautigan,et al. Raf-1 activates MAP kinase-kinase , 1992, Nature.
[12] G. Stark,et al. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21. , 2007, Cancer research.
[13] Taylor Jensen,et al. Epigenetic inactivation of the HOXA gene cluster in breast cancer. , 2006, Cancer research.
[14] Sarah A. Scott,et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. , 2009, Nature chemical biology.
[15] D. A. Foster,et al. Phospholipase D in cell proliferation and cancer. , 2003, Molecular cancer research : MCR.
[16] T. Yeatman,et al. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome. , 2008, Cancer research.
[17] W. Hahn,et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. , 2001, Genes & development.
[18] G. Stark,et al. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. , 2006, Cancer research.
[19] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[20] M. Toi,et al. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. , 1991, European journal of cancer.
[21] M. Shi,et al. Phospholipase D provides a survival signal in human cancer cells with activated H-Ras or K-Ras. , 2007, Cancer letters.
[22] M. Bissell,et al. FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. , 2012, The Journal of clinical investigation.
[23] C. Schem,et al. Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer , 2009, Breast Care.
[24] S. Elledge,et al. Normal and oncogenic p21ras proteins bind to the amino-terminal regulatory domain of c-Raf-1 , 1993, Nature.
[25] E. Kandel,et al. Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFκB , 2009, Proceedings of the National Academy of Sciences.
[26] L. Chin,et al. A Genetic Screen for Candidate Tumor Suppressors Identifies REST , 2005, Cell.
[27] J. Downward. Targeting RAS signalling pathways in cancer therapy , 2003, Nature Reviews Cancer.